Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 198 of 6351
-
Could a lower dose of radiation plus a targeted pill treat this lymphoma just as well?
Disease control Not yet recruitingMulti center, randomized, controlled, prospective clinical trial to explore the clinical efficacy and safety of low-dose radiotherapy combined with targeted therapy for localized MALT lymphoma.
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Cutting radiation after surgery: a new hope for head and neck cancer patients?
Disease control Not yet recruitingThis was a phase II clinical study. Patients with histologically confirmed, resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) without distant metastasis were enrolled. Enrolled patients received three cycles of neoadjuvant immunotherapy combined with chem…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a new drug ease bulging eyes in thyroid disease?
Disease control Not yet recruitingThis is a multicenter, randomized, double-masked, placebo-controlled Phase 3 study to evaluate the efficacy, safety, immunogenicity, and population pharmacokinetic (PopPK) characteristics of KHN939 in Chinese patients with moderate-to-severe active thyroid eye disease (TED). Appr…
Phase 3 • Sponsor: Beijing Kanghong Biological Medicine Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a gut bacteria transplant help immunotherapy wipe out rectal cancer before surgery?
Disease control Not yet recruitingTo evaluate the pathological complete response rate (pCR) of intestinal flora transplantation combined with short-course radiotherapy +CAPOX+ sintilimab in neoadjuvant therapy for locally advanced rectal cancer (pMMR/MSS type)
Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a new pill outperform standard care for ulcerative colitis?
Disease control Not yet recruitingUlcerative colitis (UC) is a chronic, relapsing inflammatory disease of the colon that causes diarrhea, bleeding, and abdominal pain. Mesalazine (5-aminosalicylic acid) is the current standard first-line treatment for mild-to-moderate UC, but many patients do not respond well eno…
Phase 4 • Sponsor: Sir Run Run Shaw Hospital • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a pill revive bone marrow in aplastic anemia?
Disease control Not yet recruitingThis research study is testing a medicine called avatrombopag in adults with aplastic anemia, a rare condition where the bone marrow does not produce enough blood cells. The study will include about 26 participants from Japan, South Korea, and Taiwan whose disease has not respond…
Phase 2/3 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug combo aims to outsmart lymphoma resistance
Disease control Not yet recruitingThis is a prospective, single-center, open-label, randomized, controlled phase II clinical trial. The main purpose of this study is to evaluate the efficacy and safety of combining brentuximab vedotin (an anti-CD30 antibody-drug conjugate, ADC) with lisaftoclax (APG-2575, a novel…
Phase 2 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a targeted antibody tame kidney inflammation without heavy steroids?
Disease control Not yet recruitingThis study is an open-label, single-arm, exploratory study designed to evaluate the efficacy and safety of Obinutuzumab beta combined with a rapid-tapering glucocorticoid regimen in patients with new-onset ANCA-associated glomerulonephritis (AAGN).
Phase 2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a triple therapy shrink untreatable liver tumors?
Disease control Not yet recruitingThis is a multicenter, retrospective study planned to enroll patients with unresectable hepatocellular carcinoma (uHCC) who received first-line donafenib combined with an anti-PD-1/L1 monoclonal antibody and either TACE or HAIC at 8 sites between June 1, 2021 and November 30, 202…
Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New hope for tough esophageal cancer: HS-20093 enters final trial
Disease control Not yet recruitingThis is a multicenter, randomized, open-label, controlled phase III clinical study to evaluate the efficacy and safety of HS-20093- injection versus investigator's choice of chemotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma after prog…
Phase 3 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug VV119 aims to tame schizophrenia symptoms
Disease control Not yet recruitingThis will be a multicenter, randomized, double-blind, placebo and active comparator parallel-controlled study designed to assess the safety and efficacy of VV119 (2.0 to 6.0 mg) for the treatment of adult participants diagnosed with DSM-5 schizophrenia who are in an acute exacerb…
Phase 2 • Sponsor: Vigonvita Life Sciences • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Can immunotherapy before or after chemoradiation beat esophageal cancer?
Disease control Recruiting nowA total of 120 patients with unresectable, locally advanced esophageal squamous cell carcinoma patients will be enrolled in this study and randomly divided into two groups. Arm A: After 2 cycles of induction adebrelimab plus chemotherapy, patients will be treated with concurrent…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
A new brain monitor could reveal stroke outcomes in minutes
Diagnosis Recruiting nowThis multicenter, prospective, and interventional diagnostic accuracy study enrolls patients undergoing thrombectomy with intraoperative cerebral autoregulation monitoring and follows them up at predefined time points up to 90 days post-enrollment.This study aims to evaluate a mo…
Sponsor: Beijing Shijitan Hospital, Capital Medical University • Aim: Diagnosis
Last updated Aug 19, 2026 00:00 UTC
-
Can a single radiation type spare prostate cancer patients from extra side effects?
Disease control Recruiting nowThe purpose of the study is to explore the best ways of giving radiation therapy to balance cancer control and treatment side effects.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a single gene therapy injection reverse fatty liver disease?
Disease control Recruiting nowA Study of VV-14303 for the Treatment of Metabolic dysfunction-associated steatohepatitis (MASH)
Phase 1/2 • Sponsor: Kriya Therapeutics, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New diabetes shot aims to rival semaglutide in blood sugar control
Disease control Not yet recruitingThis study is a multicenter, randomized, open-label, parallel-group, semaglutide injection-controlled clinical trial. It aims to evaluate the non-inferiority of UBT251 Injection in glycemic control compared with Semaglutide Injection after 36 weeks of continuous administration in…
Phase 3 • Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New antibody therapy aims to stop chronic kidney transplant rejection
Disease control Recruiting nowThis clinical trial aims to determine whether a bispecific T-cell engager (BiTE) targeting BCMA×CD3 effectively treats chronic active antibody-mediated rejection (cAMR) in kidney transplant recipients. The study also investigates the safety of BiTE in this patient population. Th…
Phase 4 • Sponsor: Turun Song • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can two immune boosters outsmart Chemo-Resistant colon cancer?
Disease control Not yet recruitingThsi study is a randomised, parallel-controlled phase II/III trial evaluating FOLFIRI plus bevacizumab with or without QL1706 as second-line therapy for metastatic colorectal cancer. The primary endpoint is PFS. Secondary endpoint includes overall survival, objective response rat…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Heart attack prevention: should doctors stent dangerous plaques early?
Disease control Not yet recruitingThe PREVENT-2 trial is to determine whether an initial invasive strategy-consisting of early coronary angiography (CAG) with intent for preventive percutaneous coronary intervention (PCI) in addition to optimal medical therapy (OMT)-reduces the incidence of the primary composite …
Sponsor: Seung-Jung Park • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Can a targeted drug boost standard chemo for aggressive lymphoma?
Disease control Not yet recruitingTo evaluate the efficacy and safety of pirtobrutinib combined with R-CHOP in patients with newly diagnosed non-GCB diffuse large B-cell lymphoma (DLBCL)
Phase 2 • Sponsor: Changzhou No.2 People's Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC